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RCe015-A (RC-11) was received as a fragmented cleavage stage em-
bryo that was surplus to requirement or unsuitable for clinical use.
Human embryonic stem cell (hESC) isolation, expansion and qualiﬁca-
tion was performed in a facilities whose speciﬁcation, operation and
monitoring complied with GMP standards enabling; i) a fully traceable
procurement procedure with informed ethical consent which includes
provision for commercial use, ii) detailed medical history and blood
borne virus (BBV) screening of donors, and iii) compilation of a cell
line history providing details on hESC manufacturing process and qual-
ity control testing regime.
Human ESC culture and processing was performed in a grade A tis-
sue culture cabinet in a grade B clean room environment monitored
for particulate andmicrobiological contamination during cell processing,
in accordance with Rules and Guidance for Pharmaceutical Manufac-
turers and Distributors – The Orange Guide, compiled by the UK Medi-
cines Healthcare Products Regulatory Authority (Go to: https://www.
gov.uk/guidance/good-manufacturing-practice-and-good-distribution-
practice). Accordingly, the facility was operating under a mature Qualitytivecommons.org/licenses/by-nc-nd/4.0/).
43P.A. De Sousa et al. / Stem Cell Research 17 (2016) 42–48Management System, compliant with ISO9001:2008 standards. Further
hESC derivation was performed under licensure from the UK HFEA
(R0136 to centre 0202) and HTA (Licensing Number 22631).
The embryo was grown to blastocyst stage and the cell line was
derived by whole embryo outgrowth on mitotically inactivated
human dermal ﬁbroblast (HDF) feeder cells. HDFs were derived and
manufactured according to GMP and had been approved for clinical
use by the Food and Drug Administration, USA. During derivation on
HDFs, hESCs were grown in a xeno-free cell therapy grade media
(XF KODMEM) supplemented with xeno-free human recombinant
bFGF. HESCs were subsequently expanded in a GMP grade serum-freeFig. 1. Quality Control Certiﬁcate of Analysimedium (StemPro hESC Serum Free Medium) and xeno-free matrix
(CellStart). The former contained bovine serum albumin (BSA) from a
Transmissible Spongioform Encephalopathy (TSE)-free country of ori-
gin. The cell line was cryopreserved in a GMP compliant cryopreserva-
tion solution (CryoStor CS10).
By ﬂow cytometry, RCe015-A (RC-11) expressed the pluripotency
makers Oct-4, Tra-1-60 and SSEA-4 (90.0%, 87.2% and 94.9%, respective-
ly), whereas low expression of the differentiationmarker SSEA-1 (0.0%)
was observed (Fig. 1, Fig. 2). Differentiation to the three germ layers,
endoderm, ectoderm and mesoderm, was demonstrated using embry-
oid body formation in vitro, and expression of the germ layer markerss for RC-11 (RCe015-A) P10A seed lot.
Fig. 1 (continued).
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panel). In vivo teratoma formation yielded typical hESC derived terato-
mas. Histological examination of ﬁxed and stained sections clearly
showed generation of cell types from ectoderm andmesoderm lineages.
Endoderm differentiation was also present, but the quality of the struc-
tures meant these could not be fully characterised (Fig. 3, bottom
panels).
A microsatellite PCR proﬁle has been obtained for the cell line, and
HLA Class I and II typing is available (Table 1). Blood group genotyping
gave the blood group O1O1, expected to give rise to blood group O+
(Table 1). The cell line is free frommycoplasma contamination as deter-
mined by RT-qPCR.Veriﬁcation and authentication
The cell line was analysed for genome stability by G-banding and
showed a normal 46XX female genotype (Fig. 4). SNP genotyping was
carried out using the Illumina HumanCytoSNP-12 v2.1 BeadChip and
revealed a 3.6 Mb Copy-Neutral Loss of Heterozygosity (CN-LOH) on
chromosome 2 (Chromosome 2p16.2-16.1) as described in Canham
et al., 2015. While CN-LOH can be constitutional acquired CN-LOH
can occur during oncogenic transformation however such changes
are almost exclusively telomeric or greater than 25 Mb when inter-
stitial (Kearney et al., 2011; Stephens et al., 2006). This region was
cross-referenced to the Genomic Imprinting database (http://www.
Fig. 2. RCe015-A (RC-11) was subjected to ﬂow cytometry analysis for markers of pluripotency with speciﬁc antibody (top row) or isotype control (bottom row) as indicated above the
histograms. Percentage staining is indicated in the Certiﬁcate of Analysis (Fig. 1).
45P.A. De Sousa et al. / Stem Cell Research 17 (2016) 42–48geneimprint.com) (Falls et al., 1999) and was found not to reside in an
imprinted region, although CCDC85A in the CN-LOH is predicted, but
not validated, to be imprinted on this database.
Materials and methods
Ethics
Derivation of hESC from surplus to requirement and failed to
fertilise/develop embryos was approved by The Scotland A ResearchFig. 3. RCe015-A (RC-11) can differentiate into the three germ layers in vitro and in vivo. Em
(ectoderm), muscle actin (mesoderm), and α-fetoprotein (endoderm). Speciﬁc staining is s
teratomas formed under the kidney capsule of mice yielded clear evidence for mesoderm andEthics Committee and local ethics board at participating fertility clinics
and conducted under licence no R0136 from the UK HFEA with in-
formed donor consent. The processing and storage of hESC cells for
human application was conducted under Licence Number 22631 from
the UK Human Tissue Authority.
Cell culture
Fresh embryos were cultured in Sydney cleavage medium (Cook
Medical, Hertfordshire, UK) until day 3 and Sydney blastocyst mediumbryoid body mediated differentiation (top panel) resulted in expression of β-tubulin III
hown in green, cell nuclei are counterstained with DAPI (blue). Histological sections of
ectoderm differentiation and indicated that endoderm structures were also present.
Table 1
Microsatellite PCR, blood group and HLA tissue typing results for RCe015-A (RC-11).
Microsatellite PCR results
D3S1358 1 D3S1358 2 vWA 1 vWA 2 D16S539 1 D16S539 2 D2S1338 1 D2S1338 2
15 16 16 17 11 13 18 19
Amelogenin 1 Amelogenin 2 D8S1179 1 D8S1179 2 D21S11 1 D21S11 2 D18S51 1 D18S51 2
X X 13 14 29 31.2 18 20
D19S433 1 D19S433 2 THO1 1 THO1 2 FGA 1 FGA 2 CSF1PO 1 CSF1PO 2
14 14 6 9 23 23 10 12
D5S818 1 D5S818 2 D7S820 1 D7S820 2 D13S317 1 D13S317 2 TPOX 1 TPOX 2
11 12 10 13 10 12 8 11
Blood group genotyping
RhD RhC Rhc RhE Rhe Fy a Fy b Fy GATA
pos pos pos pos pos neg pos neg
Jka Jkb K k M N S s
pos pos neg pos pos neg neg pos
Do a Do b ABO
pos neg O1O1
HLA tissue typing
HLA class I type HLA-A*01, A*24; B*07, B*08; Cw*07
HLA class II type HLA-DRB1*03, DRB1*15; DRB3*01; DRB5*01; DQB1*02, DQB1*06; DPB1*01, DPB1*04
Comment DRB1*03 is expressed serologically as DR17, Unable to exclude DPB1*0602, 8201.
46 P.A. De Sousa et al. / Stem Cell Research 17 (2016) 42–48(Cook Medical) after day 3 of development. Embryos were cultured at
36.5–37.5 °C, 5.0 ± 0.5% CO2, 5.0 ± 0.5% O2 in drops under parafﬁn oil
(CookMedical) and transferred to freshmedium at least every 2–3 days.Fig. 4. RCe015-A (RC-11) was analysed by Giesma staining of 30 meBy day 8 of development, embryos were placed in derivation condi-
tions consisting of mitotically inactivated GMP grade neonatal human
dermal ﬁbroblasts (HDFs) (Forticell Biosciences, NJ, USA) on tissuetaphase spreads and showed a normal 46XX female karyotype.
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XF, 2 mM L-glutamine, 1% MEM Non essential amino acids, 2% XF
Growth Factor Cocktail, 0.1 mM β-mercaptoethanol (ThermoFisher Sci-
entiﬁc, Paisley, UK) supplemented with 80 ng/ml human bFGF
(ThermoFisher Scientiﬁc). When available, cell therapy system quality
reagents were used. Assisted hatching was performed by removing
the zona pellucidaemechanically using Swemed cutting tools (Vitrolife,
Göteborg, Sweden).
HDF cells were cultured in DMEM (Lonza, Slough, UK), 10% Pharma
grade FCS (GE Healthcare (PAA), Buckinghamshire, UK) and 2 mM L-
glutamine (ThermoFisher Scientiﬁc). HDF were mitotically inactivated
using gamma irradiation at 50 Gy using a Gammacell Elite 1000 ma-
chine. For use as a feeder layer, irradiated HDFs were plated at 50,000
cells/cm2 in XF KODMEM medium supplemented with 80 ng/ml
human bFGF (ThermoFisher Scientiﬁc). Cells were cultured at 36.5–
37.5 °C, 5.0 ± 0.5% CO2, 5.0 ± 0.5% O2 and 50% medium exchanged
6 days a week.
The established cell line was expanded and banked using CellStart
matrix and Stempro hESC Serum Free Medium (cell therapy system
quality reagents, ThermoFisher Scientiﬁc). This contained BSA from a
TSE-free country of origin. Passaging was performed mechanically
using an EZ passage tool (ThermoFisher Scientiﬁc). hESC lines were ex-
panded to 25–30 wells of a 6-well plate and cryopreserved in 0.5–1 ml
Cryostor CS10 (Biolife Solution, Washington, USA) using an EF600-107
controlled rate freezer (Grant Instruments, Cambridge, UK) before
being stored in a−150 °C freezer (Panasonic Biomedical, Loughbor-
ough, UK).
Mycoplasma
In process mycoplasma detection was performed using Applied
Biosystems PrepSEQ™ Mycoplasma Nucleic Acid Extraction Kit and
MicroSEQ™ Mycoplasma Real-Time PCR Detection Kit (ThermoFisher
Scientiﬁc (Applied Biosystems)) according to the manufacturer's in-
struction. Eurpoean pharmacopoeia (EP) mycoplasma testing was car-
ried out by Moredun Scientiﬁc Ltd. (Edinburgh, UK), under a quality
and technical agreement.
Endotoxin
Endotoxin levels were determined using the Kinetic-QCL assay
(Lonza) and an incubating plate reader (BioTek ELx808) according to
the manufacturer's instructions. Brieﬂy, an unknown sample was com-
pared with a standard curve of known levels of control endotoxin. An
assay was deemed valid if the coefﬁcient of correlation, r ≥ 0.980 and
the CV (%) for the standard curve was ≤10%, and the reaction time of
the negative control was greater than the reaction time of the lowest
standard on the standard curve.
Flow cytometry
Pluripotency was determined using the Human andMouse Pluripo-
tent StemCell Analysis kit (BD,Oxford, UK). Oct 3/4 and SSEA-4were in-
cluded as pluripotencymarkers, and SSEA-1 as a differentiationmarker.
FITC conjugated Tra-1-60 (BD) was used as an additional pluripotency
marker. Fixed and permeabilised cells were analysed using a FACS
Aria ﬂow cytometer (BD) or a Guava easyCyte ﬂow cytometer
(Millipore, Watford, UK). Percentage expression of each marker was
compared to isotype control or unstained cells.
Viability
Viability was determined using the Guava ViaCount assay. Brieﬂy,
the Guava Viacount reagent (Millipore) containing a nuclear and a via-
bility dye, was mixed with a single cell suspension, incubated for 5 min
and analysed using the Guava easyCyte ﬂow cytometer (Millipore).Total cell count, viable cell count and percentage viable cells was
obtained.
In vitro differentiation
hESCs were pre-treated for 1 h with 10 μM ROCK inhibitor in
Stempro hESC SFM (ThermoFisher Scientiﬁc) and embryoid bodies
(EBs) generated in ultra low attachment plates (Corning) for 7 days be-
fore being transferred into EBmedium (20% FBS (GE Healthcare (PAA)),
80% KO-DMEM 1mM L-glutamine, 3.5 μM β-mercaptoethanol, 1% non-
essential amino acids (all ThermoFisher Scientiﬁc)), on glass slide tissue
culture chambers (Nunc, ThermoFisher Scientiﬁc) coated with 0.2% gel-
atin (Sigma Aldrich, Dorset, UK) at 0.1 ml/cm2 for 14 days.
Immunocytochemistry
Cells were ﬁxed in 4% paraformaldehyde (ThermoFisher Scientiﬁc
(Alfa Aesar)), permeabilised using 100% ethanol (ThermoFisher Scien-
tiﬁc) and stained with AFP (1:500; Sigma), β-tubulin III (1:1000;
Sigma) and muscle-speciﬁc actin (1:50; DAKO, Glostrup, Denmark)
and secondary antibody anti mouse IgG-AlexaFluor 488 (1:200;
Sigma). Images were acquired using a Zeiss S100 Axiovert ﬂuorescence
microscope or Nikon eC1 confocal microscope.
In vivo differentiation
The developmental potential of hESC lines to form teratomas
consisting of tissues representative of all three germ layers was evaluat-
ed following transplantation under kidney capsule in NOD scid gamma
mice. After three months, the animals were culled and assessed for ter-
atoma formation. Teratomas were ﬁxed in 4% paraformaldehyde, em-
bedded in parafﬁn wax and serial sections of 7 μm thickness were cut
according to standard procedures. For histological assessment, the tis-
sue sections were dewaxed, rehydrated and stained withMasson stain-
ing. Tissue sections were analysed using bright ﬁeld and microscopy
and digital images were recorded.
SNP genotyping and analysis
DNA samples were assayed using the Illumina HumanCytoSNP-12
v2.1 BeadChip. Genotyping data was initially assessed using
GenomeStudio genotyping module (v1.94, Illumina). Karyostudio
(v1.4, Illumina) was employed to perform automatic normalisation
and to identify genomic aberrations utilising default settings of the
built-in cnvPartition algorithm (3.07, Illumina) to generate B-allele fre-
quency and smoothened Log R ratio plots for detected regions. These
parameters are designed to detect CNVs greater than 75 kb and CN-
LOH regions larger than 1 MB with a conﬁdence value greater than 35.
All identiﬁed regions were ﬁrst cross-matched to the Database of Geno-
mic Variants (DGV; http://dgv.tcag.ca) to identify naturally-occurring
structural variations in the human. CNVs that were not identiﬁed on
the DGV were then checked against a list of ES cell-associated culture
adaptation genomic variants published by the International Stem Cell
Initiative (Amps et al., 2011). See also Canham et al., 2015 for further
details.
Genomic analysis and outsourced assays
All outsourced assays were carried out under a Quality and Tech-
nical Agreement. DNA was extracted using the QIAamp DNAMini kit
(Qiagen, Manchester, UK) according to manufacturer's recommen-
dations and provided in recommended quantities to the service
providers.
Microsatellite PCR, or Short Tandem Repeat analysis, was used to
determine cell line identity and was carried out by Public Health
England. A proﬁle was obtained for the following core alleles: vWA,
48 P.A. De Sousa et al. / Stem Cell Research 17 (2016) 42–48D16S539, Amelogenin, THO1, CSF1PO, D5S818, D75820, D135317 and
TPOX.
Human Leukocyte Antigen (HLA) tissue typing was carried out by
the Scottish National Blood Transfusion Service.
Blood group genotyping was carried out by the Molecular Diagnos-
tics laboratory at NHSBT.
Karyotype analysis was carried out by The Doctors Laboratory
(London, UK) or the Western General Cytogenetics Laboratory (Edin-
burgh, UK). Live cells at 60–70% conﬂuency were shipped in warm con-
tainers, ﬁxed and analysed by standard G-banding analysis. For clinical
grade lines, 30 spreads were analysed.
Viral screening for cytomegalovirus (CMV), Human T-cell
lymphotropic virus (HTLV)-1, Human immunodeﬁciency virus (HIV)-
1, Hepatitis C virus (HCV), Hepatitis B virus (HBV) and Epstein–Barr
virus (EBV) was carried out by The Doctors Laboratory.
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